Axsome Therapeutics Initiates FOCUS-3 Phase 3 Trial of Solriamfetol in Adolescents with Attention Deficit Hyperactivity Disorder Life Science Investing
Taysha Gene Therapies Announces Multiple Presentations Highlighting its TSHA-102 Clinical Program at the 2026 IRSF Rett Syndrome Scientific Meeting Life Science Investing
NRx Pharmaceuticals Responds to Recent Public Statements Regarding Kadima Dispute Life Science Investing
PRF Technologies Reports Expanded Preclinical Results for PRF-110 in Head-to-Head Comparison with Approved Benchmark Life Science Investing
BioRestorative Therapies Announces Completion of BRTX-100 Phase 2 Manufacturing, Highlighting Integrated Regenerative Biologics Platform Life Science Investing
BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT Pharmaceutical Investing
Tiziana Announces Last Patient Successfully Dosed in its Phase 2 INFORM-MS Trial Life Science Investing
BriaCell and BriaPro Present Positive Preclinical Immunotherapy Data Across Four Posters at SITC 2026
BriaCell and BriaPro to Present Preclinical Anti-Cancer Activity and Immunotherapy Findings at SITC 2026Â
